Price movement over the last 24 hours
AFLAC Incorporated vs Canopy Growth Corp — how do they compare? AFLAC Incorporated trades at $121.27 (market cap $61.84B), while Canopy Growth Corp trades at $0.96 (market cap $404.40M). The key difference: AFLAC Incorporated is far larger — about 152.9× Canopy Growth Corp's market cap, and AFLAC Incorporated pays a 2.01% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| AFL | CGC | |
|---|---|---|
Market Cap | $61.84B | $404.40M |
Sector | Financials | Health |
52-Week High | $121.49 | $1.92 |
52-Week Low | $98.09 | $0.86 |
Enterprise Value | $70.50B | $343.85M |
Dividend Yield | 2.01% | — |
Signals from Pluang's Aura AI — not financial advice
Aflac (AFL) trades at $121.49, up 0.5% with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a 25.32% net income margin and 16.47% ROE, though recent Q1 2026 earnings missed expectations. Analyst consensus is mixed with 28% buy ratings and a $113.57 price target below current levels. Recent developments include strong dividend performance and upcoming Q2 2026 results announcement on August 6, 2026.
The outlook remains cautiously optimistic with solid profitability and dividend stability, but faces headwinds from recent earnings misses and premium valuation pressure. Key opportunities include continued growth in Japan and U.S. markets, while risks involve medical cost inflation and uneven revenue trends. The stock's current premium to analyst targets suggests limited near-term upside potential.
CGC trades at $0.95, down 5% on the day, with a bearish technical signal and negative earnings momentum after recent quarterly misses. The company reported a net loss of $598.12 million in 2025, with a net income margin of -222.36%, though revenue trends show some stabilization. Cash flow remains negative, and the stock faces Nasdaq listing compliance risks due to its low price, with news highlighting potential for a reverse stock split.
The outlook is highly speculative with significant operational and financial risks. While valuation ratios like P/S of 1.44 and P/B of 0.83 appear modest, persistent losses and high debt levels overshadow any near-term upside. Investor sentiment is mixed among analysts, with a slight hold bias, but the path to profitability remains uncertain amid competitive and regulatory pressures.
Trailing returns across standard periods
Latest headlines on both assets
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →